The first time I heard Don talk about CVR's was a few years ago, to me he seemed to view them positively. Personally I would love to see RVX taken out in a CVR deal as to me it derisks this investment from a few perspectives. 1) it puts money into investors hands immediately 2)it puts the Apabetalone in hands that can afford to see Apabetalone through BetOnMace and if successful take it to registration thereby create more return for investors 3)it puts the other IP into hands that have the financial and management capabilities to move these programs forward and again potentially put more money in investors hands in a more timely fashion than current management seems capable of. 

To me one of the key risks to RVX has always been mediocre management, we have heard about many promising opportunities but have seen little or no forward progress on most. CKD trial, anpticipatex to start today (after being delayed) - didn't see an announcement. 6-7 clinic ready compounds - no action. Priority Review Voucher talk from a couple of years ago - no action. New, real analyst coverage and many other items on the bygone corporate checklist- no action. Yes I would love to see a CVR deal done which would put immediate money in investors hands, likely put all the IP on a clearer path forward and completely remove the risk associated with current management. All my opinion